Search PubMed⌕ Search

Biomedical subjects

J Sany

Publications and source records attributed to J Sany.

At least 181 records · Page 10Linked to original sources
PubMed1984

Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.

Previous reports have shown that serum beta-2-microglobulin (S beta2M) is a reliable marker of presenting tumor mass, response to chemotherapy, and prognosis of patients with multiple myeloma (MM). In order to more thoroughly evaluate the optimal use of S beta2M in plasma cell dyscrasias (PCD), S beta2M levels were serially measured in 160 patients with MM, in comparison with 37 normal controls (NC) and 28 patients with monoclonal gammopathy of undetermined significance (MGUS). In MGUS, S beta2M did not differ significantly from that of NC, but was significantly lower than that of MM (p less than 0.001), including low cell mass MM (p less than 0.02). In MM, S beta 2M was highly correlated with the total body burden of myeloma cells as derived from the staging of Durie and Salmon, both at diagnosis and in remission (residual tumor mass) (p less than 0.001). During the plateau phase, S beta 2M remained very stable and was always within the normal range for patients with greater than or equal to 75% tumor regression. The most striking finding was that S beta 2M gave an extremely reliable fit for survival prediction at (1) diagnosis, (2) remission, and (3) early relapse, with higher S beta 2M levels in each instance being in favor of poorer prognosis. We conclude that S beta 2M is an extremely useful marker in initial stratification and follow-up of patients with MM.

Humans↗
PubMed1983

[HLA-DR determinations in peripheral psoriatic rheumatism].

The distribution of 7 HLA-DR antigens was compared in 25 patients with peripheral psoriatic rheumatism and in 100 healthy controls. DR7 frequency was found to be significantly increased in patients: 60%, against 27% in controls (Pc = 0.021). Peripheral psoriatic rheumatism, which is related with HLA antigens B17, B13, Bw38 and Cw6, is probably also associated with DR7.

B-Lymphocytes↗
PubMed1983

Serum beta-2-microglobulin binding activity in monoclonal gammopathy: correlative study and clinical significance.

Serum beta 2m binding activity (S beta 2m-BA) was determined by a polyethylene glycol exclusion test of radiolabeled human beta 2m in 185 serum samples from 62 patients with multiple myeloma (MM). Elevated S beta 2m-BA was found in more than half of the samples from IgG myeloma taken before treatment or during progression of the disease but not during the plateau-phase. Conversely, elevated S beta 2m-BA was found in only one case of IgA myeloma, one case of monoclonal gammopathy of undetermined significance and none of the Bence Jones myelomas. S beta 2m-BA appears to be related to disease progression in IgG myeloma. The activity is supported by minute amounts of serum autoantibodies which are distinct from the monoclonal component. S beta 2m-BA was independent from serum beta 2m levels.

Adult↗
PubMed1983

[Articular manifestations of Yersinia infections. Apropos of 4 personal cases. Review of the literature].

The reactive arthritis due to Yersinia enterocolitica (YEC) have been know for a little more than ten years. A great many cases have been reported, especially by Scandinavian authors. In contrast, few cases have been reported in the course of Yersinia pseudotuberculosis infections (YPT). Analysis of 36 cases in the literature shows that although they are rare, the YPT reactive arthritis do exist and are not fundamentally different from those due to YEC. A few minor differences in their clinical signs have been demonstrated: the higher incidence of erythema nodosa and the lower incidence of cardiac involvement in the cases due to YPT. In both forms, there is a characteristic genetic predisposition, marked by the high incidence of the antigen HLB B27 (50 to 80 p. cent), which explains their strict relationship with diseases of the rheumatic pelvispondylitis group.

Adolescent↗
PubMed1983

[Assay of rheumatoid factor by laser nephelometry. A study of 1,000 sera].

The detection and assay of Rheumatoid Factor (RF) are possible using laser nephelometry as the reaction between circulating RF and aggregated human IgG results in the formation of soluble immune complexes which scatter the light emitted by the laser. The use of this new method in 1,000 sera shows that this test is more sensitive, positive earlier and more reproducible than the usual reactions of passive agglutination. Its complete automation makes it very rapid and very reliable.

Arthritis, Rheumatoid↗
PubMed1982

[Anemia in rheumatoid polyarthritis. Value of serum ferritin for the estimation of iron stores].

Biochemical evaluation of iron depletion due to bleeding is difficult in rheumatoid arthritis (RA) patients with inflammatory anaemia. The authors have tried to assess the usefulness of serum ferritin (SF) level measurements--considered a reliable index of iron stores--by comparing the values obtained with true iron stores, as determined by Perls' test on bone marrow. The study involved 50 RA patients with anaemia and raised erythrocyte sedimentation rate (ESR). The poor correlation (r = 0.51) observed between the two tests in this population was mainly due to differences in ESR. SF levels and Perls' test results correlated better in patients with an ESR above 50 mm/h. (r = 0.69) than in patients with an ESR above 50 mm/h. (r = 0.44). The mean ESR values were higher than those found in patients without inflammatory syndrome. SF levels, therefore, are unreliable in patients with inflammatory syndrome, and no practical conclusion concerning iron stores can be drawn from the finding of a normal SF level. In the present study, only SF levels higher than 250 ng/ml were associated with positive Perls' tests. The behaviour of ferritin in the presence of inflammation may explain the results obtained.

Anemia, Hypochromic↗
PubMed1982

Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis.

Patients who had active and severe rheumatoid arthritis (RA) were treated with human placenta-eluted gamma globulins (PEGG) composed of purified IgG eluted from trophoblastic cells. A control group of RA patients received retroplacental gamma globulins with no clinical effects. Seven of eleven treatments with PEGG showed good (4 patients) or very good (3 patients) clinical results. All patients had immunologic modifications demonstrated by a significant increase in active E-rosette-forming cells and mitogen responsiveness. The precise mechanism of immunomodulating effect of PEGG should be further investigated.

Adult↗
PubMed1982

Clinical evaluation of myeloma osteoclastic bone lesions: II. Induced hypocalcemia test using salmon calcitonin.

Acute effects of salmon calcitonin (SCT) were tested by an SCT induced hypocalcemia test (SCT delta Ca test) in 70 cases of multiple myeloma (MM) (including 52 untreated patients) with bone involvement. Response to SCT in terms of maximum induced hypocalcemia (M delta Ca) was compared to normal controls (NC) and correlated with the main presenting features and clinical status. Acute effects are significantly more marked in MM than in NC (p less than .001). There is a good correlation with the extent of lytic bone lesions (p less than .01), the presence of hypercalcemia (p less than .02) and the myeloma cell mass (p less than .05). After correction for bone involvement response to SCT (M delta Ca) was stronger in IgA lambda MM than in IgG kappa (p less than .01). It is of particular interest that acute effects are significantly more marked in cases of active disease than in non-active disease. We conclude that the SCT delta Ca test might be of practical value in the management of MM.

Aged↗
PubMed1982

Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.

Serum beta-2-microglobulin (B2m) levels were measured in 78 patients with multiple myeloma (MM) and were compared with values for normal individuals and patients with benign monoclonal gammopathies (BMG). Serum B2m levels and values corrected for renal function were significantly higher in patients with MM at time of diagnosis than in normal individuals (P less than 0.001) and were highly correlated with the total body burden of myeloma cells as derived from the staging system of Durie and Salmon. However there were no significant differences between values for BMG and low-mass MM. For patients evaluated following induction chemotherapy, there was also a clear correlation between serum B2m levels and the magnitude of tumor regression or progression (P less than 0.05). During the plateau-phase, serum B2m levels remained very stable and highly correlated with the residual tumor mass (P less than 0.001). It was concluded that (1) B2m was not a reliable marker to distinguish between BMG and low-mass MM and (2) B2m was a valuable marker for assessing initial tumor mass of patients with MM and response to chemotherapy (especially the plateau-phase), above all in patients with urine or low-serum monoclonal component levels.

Antineoplastic Agents↗
PubMed1982

Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients.

Radiography and scintigraphy were correlated in 70 patients with recently diagnosed, untreated multiple myeloma, including 59 with and 11 without primary lytic bone lesions. A site-by-site comparison showed that scintigraphy was more sensitive than radiography in only 18% of cases, whereas radiography was more sensitive in 38% (p less than 0.001). Patients whose bone scan was as sensitive or more so than the radiograph ("hot" myeloma) had more active disease than those with the "cold" form. Remission was indicated by significant regression or disappearance of scintigraphic abnormalities in 90% of cases. The authors conclude that scintigraphy is not helpful in detecting myelomatous bone lesions, but does have prognostic value for diagnosis and chemotherapy: a positive bone scan indicates initial or residual activity.

Adult↗
PubMed1982

beta 2-Microglobulin and beta 2-microglobulin-binding proteins in inflammatory diseases.

Beta 2 microglobulin (beta 2m) is a 11,800 daltons polypeptide non covalently associated with the heavy chain of class I histocompatibility antigens (HLA-A, B and C) at the surface of nearly all cells. Serum beta 2m levels are passively controlled by the glomerular filtration rate. Increased beta 2m production resulting in elevated serum levels despite normal renal function have been reported in malignancies of the lymphoreticular system (e.g. multiple myeloma) and in various autoimmune or chronic inflammatory diseases, including rheumatoid arthritis. In some situations beta 2m levels were shown to be positively correlated with absolute lymphocyte counts in the peripheral blood or with the score of mononuclear cell infiltrates in biopsy specimens. Together with the demonstration that activated T lymphocytes release beta 2m in culture, these data support the hypothesis that increased production of beta 2m in vivo could represent a non specific indication of lymphocyte activation. Follow-up studies of individual patients are needed to define the clinical situations in which beta 2m determination may improve the immunological monitoring, with special reference to the early diagnosis of relapses and the assessment of individual response to treatment.

Arthritis, Rheumatoid↗
PubMed1981

Solitary myeloma: clinical and prognostic features of a review of 114 cases.

Within plasma cell disorders, solitary myeloma is rare as compared with multiple myeloma. In order to evaluate their relationship, the clinical findings for 114 patients with solitary myeloma were compared with those for 70 patients having classic multiple myeloma. The period of follow up ranged from a few weeks to twenty-four years, and 68.5% of those with solitary myeloma alive at ten years. Although only 23% of patients with solitary myeloma had local or widespread recurrence after two years, at ten years 85% had experienced disease progression. Comparison of the 85% with disease progression with patients with multiple myeloma revealed that solitary myeloma occurred at a younger age (mean 52.1 years), more frequently in men (60.5%), less commonly with initial spinal involvement (61.8%), but more commonly with neurologic problems associated with spinal involvement (25%), and that much more commonly, no monoclonal component was detectable in serum and/or urine at the time of initial diagnosis (82.5%). There were only two significant differences between those patients with (85%) and without (15%) progression at ten years; the patients were younger (mean, 45.7 years) and spinal involvement (26.7%). However, was less common among patients without progression, and component monoclonal always disappeared following treatment with surgery and/or radiation therapy. It is thus concluded that solitary myeloma and multiple myeloma are clearly different clinical entities; however, most patients with solitary myeloma do eventually have multiple myeloma.

Adult↗
PubMed1981

[Apparently isolated plasmacytoma of bone. Clinical and prognostic data. 114 cases and review of literature (author's transl)].

The authors review 114 cases (including 18 personal cases) of apparently isolated plasmacytoma of bone (AIPB) followed-up for periods of a few weeks to 24 years. The number of patients still alive, without recurrence and/or extension to the bone marrow sharply dropped from 77% after 2 years to 15% after 10 years. At the time of diagnosis, AIPB with secondary medullary involvement differed from conventional multiple myeloma of bone on six points: mean age 52,1 versus 63,2 years (p less than 0,001); male prevalence 60,5% vs 38,5% (p less than 0,02); spinal involvement 61,8% vs 88,7% (p less than 0,05); radiological aspect of giant cell tumour 33,3% vs 3% (p less than 0,001); cord involvement 25% vs 5,4% (p less than 0,001); lack of monoclonal component 82,5% vs 4,3% (p less than 0,001). On the other hand, after 10 years there were only three differences between AIPB with and without secondary extension to the bone marrow: mean age 52,1 vs 45,7 years (p less than 0,1); spinal involvement 61,8% vs 26,7% (p less than 0,01); loss of monoclonal component after local treatment 29% vs 100% (p less than 0,05). These data suggest that isolated (i.e. localized) and multiple (i.e. disseminated) myelomas are distinct manifestations of bone marrow malignant plasma cell dyscrasias and that the patient's age, the site of the tumour and the disappearance of the monoclonal component are relevant to the prognosis of the disease.

Adult↗